Literature DB >> 27325105

Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis.

Lucia Masarova1, Wei Wang2, Kate J Newberry1, Hagop Kantarjian1, Srdan Verstovsek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27325105      PMCID： PMC4982456          DOI： 10.1182/blood-2016-03-705012

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  15 in total

1.  JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

Authors:  Lisa Pieri; Alessandro Pancrazzi; Annalisa Pacilli; Claudia Rabuzzi; Giada Rotunno; Tiziana Fanelli; Paola Guglielmelli; Rajmonda Fjerza; Chiara Paoli; Srdan Verstovsek; Alessandro M Vannucchi
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

2.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

4.  The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

Authors:  Ruben A Mesa; Joyce Niblack; Martha Wadleigh; Srdan Verstovsek; John Camoriano; Sunni Barnes; Angelina D Tan; Pamela J Atherton; Jeff A Sloan; Ayalew Tefferi
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

5.  Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael W N Deininger; Carole B Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth O Hexner; Roger M Lyons; Azra Raza; Kris Vaddi; William Sun; Wei Peng; Victor Sandor; Hagop Kantarjian
Journal:  Haematologica       Date:  2015-01-23       Impact factor: 9.941

6.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

7.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

8.  The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.

Authors:  Michael Deininger; Jerald Radich; Timothy C Burn; Reid Huber; Dilan Paranagama; Srdan Verstovsek
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113

9.  The human androgen receptor X-chromosome inactivation assay for clonality diagnostics of natural killer cell proliferations.

Authors:  Michaël Boudewijns; Jacques J M van Dongen; Anton W Langerak
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

10.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Authors:  G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi
Journal:  Leukemia       Date:  2007-08-30       Impact factor: 11.528
View more
  3 in total

1.  A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.

Authors:  Prithviraj Bose; Mahesh Swaminathan; Naveen Pemmaraju; Alessandra Ferrajoli; Elias J Jabbour; Naval G Daver; Courtney D DiNardo; Yesid Alvarado; Musa Yilmaz; Julie Huynh-Lu; Wei Qiao; Xuemei Wang; Aurelio Matamoros; Lingsha Zhou; Sherry Pierce; Kurt D Schroeder; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2019-01-11

Review 2.  Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.

Authors:  David M Ross; Jeffrey J Babon; Denis Tvorogov; Daniel Thomas
Journal:  Haematologica       Date:  2021-05-01       Impact factor: 9.941

3.  Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.

Authors:  Denis Tvorogov; Chloe A L Thompson-Peach; Johannes Foßelteder; Mara Dottore; Frank Stomski; Suraiya A Onnesha; Kelly Lim; Paul A B Moretti; Stuart M Pitson; David M Ross; Andreas Reinisch; Daniel Thomas; Angel F Lopez
Journal:  EMBO Rep       Date:  2022-02-14       Impact factor: 8.807
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.